Therapeutic drug monitoring in epileptology and psychiatry;"Therapeutic drug monitoring" in epileptologie und psychiatrie

Nervenarzt

Volumn 79, Issue 2, 2008, Pages 167-174

  Brandt, C ^a   Baumann, P ^b   Eckermann, G ^c   Hiemke, C ^d   May, T W ^e   Rambeck, B ^e   Pohlmann Eden, B ^a  

^a EPILEPSY CENTER BETHEL   (Germany)

^b Unité de Biochimie et Psychopharmacologie Clinique   (Switzerland)

^c Psychiatrische Klinik   (Germany)

^d UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^e Pharmakologisches Labor der Gesellschaft für Epilepsieforschung E V   (Germany)

Author keywords

Antidepressants; Antiepileptic drugs; Neuroleptica; Therapeutic drug monitoring

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BROMIDE; CARBAMAZEPINE; ETHOSUXIMIDE; ETIRACETAM; FELBAMATE; GABAPENTIN; LAMOTRIGINE; MESUXIMIDE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; SULTIAME; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

BLOOD LEVEL; DRUG COST; DRUG MONITORING; EPILEPSY; FINANCIAL MANAGEMENT; HEALTH CARE SYSTEM; HUMAN; LABORATORY; MENTAL DISEASE; PHARMACOGENETICS; PSYCHIATRY; PSYCHOPHARMACOLOGY; REVIEW;

ANTICONVULSANTS; COST-BENEFIT ANALYSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; DRUG THERAPY, COMBINATION; EPILEPSY; GERMANY; HUMANS; MENTAL DISORDERS; NATIONAL HEALTH PROGRAMS; PSYCHOTROPIC DRUGS;

EID: 38949161475     PISSN: 00282804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00115-007-2325-x     Document Type: Review

References (42)

1. Aravagiri M, Teper Y, Marder SR (1999) Pharmacokinetics and tissue distribution of olanzapine in rats. Biopharm Drug Dispos 20: 369-377
2. Baumann P, Eap CB (2002) Pharmacogenetics of chiral psychotropic drugs. In: Lerer B (ed) Pharmacogenetics of Psychotropic Drugs. Cambridge University Press, Cambridge, pp 181-214
3. Baumann P, Hiemke C, Ulrich S et al. (2004) The AGNP-TDM expert group consensus guidelines: Therapeutic drug monitoring in psychiatry. Pharmacopsychiatry 37: 243-265
4. Baumann P, Kosel M, Voirol P (2000) Pharmakogenetische Charakterisierung - Pharmakogenetik in der Psychopharmakologie. In: Gastpar M, Banger M (Hrsg) Laboruntersuchungen in der psychiatrischen Routine. Georg Thieme Verlag, Stuttgart New York, S 134-149
5. Bertilsson L, Dahl ML, Dalen P, Al Shurbaji A (2002) Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br J Clin Pharmacol 53: 111-122
6. Bondolfi G, Eap CB, Bertschy G et al. (2002) The effect of fluoxetine on the pharmacokinetics and safety of risperidone in psychotic patients. Pharmacopsychiatry 35: 50-56
7. Brandt C, Pohlmann-Eden B (2006) Interaktionen zwischen Antiepileptika und Psychopharmaka. Z Epileptol 19: 95-108
8. Clement Jerdi et al. (2004) J Pharmaceutical Biomed Analysis 35: 1203
9. DeVane CL, Boulton DW, Miller LF, Miller RL (1999) Pharmacokinetics of trazodone and its major metabolite m-chlorophenylpiperazine in plasma and brain of rats. Int J Neuropsychopharmacol 2: 17-23
10. Dolder CR, Lacro JP, Dunn LB, Jeste DV (2002) Antipsychotic medication adherence: is there a difference between typical and atypical agents? Am J Psychiatry 159: 103-108
11. El Ela AA, Hartter S, Schmitt U et al. (2004) Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds- implications for pharmacokinetics of selected substrates. J Pharm Pharmacol 56: 967-975
12. Fromm MF (2004) Importance of P-glycoprotein at blood-tissue barriers. Trends Pharmacol Sci 25: 423-429
13. Gaertner I, Gaertner HJ, Vonthein R, Dietz K (2001) Therapeutic drug monitoring of clozapine in relapse prevention: a five-year prospective study. J Clin Psychopharmacol 21: 305-310
14. Gerloff T (2004) Impact of genetic polymorphisms in transmembrane carrier-systems on drug and xenobiotic distribution. Naunyn Schmiedebergs Arch Pharmacol 369: 69-77
15. Glotzbach RK, Preskorn SH (1982) Brain concentrations of tricyclic antidepressants: single-dose kinetics and relationship to plasma concentrations in chronically dosed rats. Psychopharmacology (Berl) 78: 25-27
16. Hiemke C, Dragicevic A, Gründer G et al. (2004) Therapeutic monitoring of new antipsychotic drugs. Ther Drug Monit 26: 156-160
17. Hiemke C, Baumann P, Laux G, Kuss H-J (2005) Therapeutisches Drug Monitoring in der Psychiatrie. Konsensus-Leitlinie der AGNP. Psychopharmakotherapie 12: 166-182
18. Hirsch LJ, Weintraub D, Du Y, Buchsbaum R et al. (2004) Correlating lamotrigine serum concentrations with tolerability in patients with epilepsy. Neurology 63: 1022-1026
19. Ingelman-Sundberg M (2001) Genetic susceptibility to adverse effects of drugs and environmental toxicants - The role of the CYP family of enzymes. Mutat Res 482: 11-19
20. Jaquenoud Sirot E, Velden JW van der, Rentsch K et al. (2006) TDM and pharmacogenetic tests as tools in Pharmacovigilance. Drug Saf 29: 735-768
21. Johannessen SI, Tomson T (2006) Pharmacokinetic variability of newer antiepileptic drugs: When is monitoring needed? Clin Pharmacokinet 45: 1061-1075
22. Kirchheiner J, Brøsen K, Dahl ML et al. (2001) CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr Scand 104: 173-192
23. Liston HL, Markowitz JS, DeVane CL (2001) Drug glucuronidation in clinical psychopharmacology. J Clin Psychopharmacol 21: 500-515
24. Lundmark J, Bengtsson F, Nordin C et al. (2000) Therapeutic drug monitoring of selective serotonin reuptake inhibitors influences clinical dosing strategies and reduces drug costs in depressed elderly patients. Acta Psychiatr Scand 101: 354-359
25. Mann K, Hiemke C, Lotz J et al. (2007) Appropriateness of plasma level determinations for lithium and anticonvulsants in routine care of psychiatric inpatients with affective disorders. J Clin Psychopharmacol (submitted)
26. Mann K, Hiemke C, Schmidt LG, Bates DW (2006) Appropriateness of therapeutic drug monitoring for antidepressants in routine psychiatric inpatient care. Ther Drug Monit 28: 83-88
27. Marzolini C, Paus E, Buclin T, Kim RB (2004) Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther 75: 13-33
28. May TW, Rambeck B, Jürgens U (1999) Influence of oxcarbazepine and methsuximide on lamotrigine concentrations in epileptic patients with and without valproic acid comedication: results of a retrospective study. Ther Drug Monit 21: 175-181
29. Meyer JH, Wilson AA, Sagrati S et al. (2004) Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. Am J Psychiatry 161: 826-835
30. Meyer UA (2000) Pharmacogenetics and adverse drug reactions. Lancet 356: 1667-1671
31. Preskorn SH, Fast GA (1991) Therapeutic drug monitoring for antidepressants: Efficacy, safety, and cost effectiveness. J Clin Psychiatry [Suppl 6] 52: 23-33
32. Rambeck B, Kurlemann G, Stodieck SR et al. (1997) Concentrations of lamotrigine in a mother on lamotrigine treatment and her newborn child. Eur J Clin Pharmacol 51: 481-484
33. Reimers A, Skogvoll E, Sund JK, Spigset O (2005) Drug interactions between lamotrigine and psychoactive drugs: evidence from a therapeutic drug monitoring service. J Clin Psychopharmacol 25: 342-348
34. Rice DP (1999) The economic impact of schizophrenia. J Clin Psychiatry 60: 4-6
35. Sabers A, Buchholt JM, Uldall P, Hansen EL (2001) Lamotrigine plasma levels reduced by oral contraceptives. Epilepsy Res 47: 151-154
36. Scordo MG, Spina E (2002) Cytochrome P450 polymorphisms and response to antipsychotic therapy. Pharmacogenomics 3: 201-218
37. Sidhu J, Job S, Singh S, Philipson R (2006) The pharmacokinetic and pharmacodynamic consequences of the co-administration of lamotrigine and a combined oral contraceptive in healthy female subjects. Br J Clin Pharmacol 61: 191-199
38. Specht U, Elsner H, May TW et al. (2003) Postictal serum levels of antiepileptic drugs for detection of noncompliance. Epilepsy Behav 4: 487-495
39. Vuille F, Amey M, Baumann P (1991) Use of plasma level monitoring of antidepressants in clinical practice. Towards an analysis of clinical utility. Pharmacopsychiatry 24: 190-195
40. Wolf P (1991) Antiepileptika haben keinen therapeutischen Bereich. Dtsch Med Wochenschr 116: 631-633
41. Wyatt RJ, Henter I, Leary MC, Taylor E (1991) An economic evaluation of schizophrenia. Soc Psychiatr Epidemiol 30: 196-205
42. Zernig G, Lechner T, Kramer-Reinstadler K et al. (2004) What the clinician still has to be reminded of. Ther Drug Monit 26: 582